Biological agents in kidney transplantation: belatacept is entering the field

Bibliography

• Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008;68(Supp l):3-10
   PubMedGoogle Scholar
• Audard V, Matignon M, Dahan K, Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transpl Int 2008;21(1):11-17
   PubMed Web of Science ®Google Scholar
• Wormer KL, Kaplan B. Recent developments in kidney transplantation: a critical assessment. Am J Transplant 2009;9(6):1265-71
   PubMed Web of Science ®Google Scholar
• Galliford J, Games DS. Modern renal transplantation: present challenges and future prospects. Postgrad Med J 2009;85(1000):91-101
   PubMed Web of Science ®Google Scholar
• Chadban S, Morris R, Hirsch HH, Immunosuppression in renal transplantation: some aspects for the modern era. Transplant Rev (Orlando) 2008;22(4):241-51
   PubMedGoogle Scholar
• Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis 2009;16(4):226-33
   PubMed Web of Science ®Google Scholar
• Cruzado JM, Bestard O, Grinyo JM. New immunosuppressive protocols with the advent of novel biological drugs. Transplantation 2009;88(3 Suppl):S20-3
   Google Scholar
• Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69(16):2227-43
   PubMed Web of Science ®Google Scholar
• Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125(8):1747-54
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, The natural history of chronic allograft nephropathy. New Engl J Med 2003;349(24):2326-33
   PubMedGoogle Scholar
• Flechner S. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc 2008;40(Suppl 10):S25-8
   Google Scholar
• Stallone G, Infante B, Gesualdo L. There is a choice for immunosuppressive drug nephrotoxicity: is it time to change? J Nephrol 2009;22(3):326-32
   PubMed Web of Science ®Google Scholar
• Lebranchu Y. New approaches to de novo immunosuppression and steroid elimination. Transplant Proc 2009;41(Suppl 6):S39-41
   Google Scholar
• Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010;23(2):133-42
   PubMed Web of Science ®Google Scholar
• Morales JM, Campistol JM, Kreis H, Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc 2005;37(2):693-6
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Segoloni G, Campistol JM, Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005;18(1):22-8
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5(10):2521-30
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H Jr, Pascual J. Authors' reply to Ekberg, et al. ‘no robust conclusions to be drawn from clinical trials in the absence of an adequate control group’. Transplant Int 2007;20(6):563-4
   PubMed Web of Science ®Google Scholar
• Campistol JM, Eris J, Oberbauer R, Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17(2):581-9
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87(2):233-42
   PubMed Web of Science ®Google Scholar
• Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transplant Int 2008;21(3):207-17
   PubMed Web of Science ®Google Scholar
• Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 2009;87(Suppl 8):S19-22
   Google Scholar
• Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008;8(7):1367-73
   PubMed Web of Science ®Google Scholar
• Cruzado JM, Bestard O, Grinyo JM. Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies. Contrib Nephrol 2009;162:117-28
   PubMed Web of Science ®Google Scholar
• Briggs D, Zehnder D, Higgins RM. Development of non-donor-specific HLA antibodies after kidney transplantation: frequency and clinical implications. Contrib Nephrol 2009;162:107-28
   PubMed Web of Science ®Google Scholar
• Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010;15(1):8-10
   PubMed Web of Science ®Google Scholar
• Bromley SK, Burack WR, Johnson KG, The immunological synapse. Annu Rev Immunol 2001;19:375-96
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Brady W, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1(9):793-801
   PubMed Web of Science ®Google Scholar
• Finger EB, Bluestone JA. When ligand becomes receptor-tolerance via B7 signaling on DCs. Nat Immunol 2002;3:1056-7
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F, CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3(1):1097-101
   PubMedGoogle Scholar
• Chavez H, Beaudreuil S, Abbed K, Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007;17(4):243-8
   PubMed Web of Science ®Google Scholar
• Akalin E, Chandraker A, Russel M, CD28-B7 T cell costimulatory blockade by CTLA4lg in the rat renal allograft model 1.2: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 1996;62(12):1942-5
   PubMed Web of Science ®Google Scholar
• Larsen CP, Elwood ET, Alexander DZ, Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathway. Nature 1996;381(6581):434-8
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Zeng Y, Thistlethwaite JR, Long-term survival of xenogeneic pancreatic islet grafts induced by CTL4lg. Science 1992;257(5071):789-92
   PubMed Web of Science ®Google Scholar
• Pearson T, Alexander D, Winn K, Transplantation tolerance induced by CTL4-lg1. Transplantation 1994;57(12):1701-5
   PubMed Web of Science ®Google Scholar
• Turka LA, Linsley PS, Lin H, T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89(22):11102-5
   PubMed Web of Science ®Google Scholar
• Kirk AD, Harlan DM, Armstrong NN, CTL4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94(16):8789-94
   PubMed Web of Science ®Google Scholar
• Kirk AD, Tadaki DK, Celniker A, Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001;72(3):377-84
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010;37(3):234-45
   PubMedGoogle Scholar
• Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008;121(2):299-306
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, Costimulation blockade with Belatacept in renal transplantation. N Engl J Med 2005;353(8):770-81
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010. [Epub ahead of print]
   Google Scholar
• Bluestone JA, Liu W, Yabu JM, The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008;8(10):2086-96
   PubMed Web of Science ®Google Scholar
• Lucchese B. Transplantation: encouraging results for belatacept immunosuppression in renal transplantation. Nat Rev Nephrol 2010;6(5):247
   PubMedGoogle Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (Benefit Study). Am J Transplant 2010;10(3):535-46
   PubMed Web of Science ®Google Scholar
• Larsen CP, Grinyo J, Charpentier B, Belatacept vs ciclosporine in kidney transplant recipients: two-year outcomes from the BENEFIT study. Am Transplant Congress 2010;82: abstract 142
   Google Scholar
• Durrbach A, Pestana JM, Pearson T, A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (Benefit Study). Am J Transplant 2010;10(3):547-57
   PubMed Web of Science ®Google Scholar
• Durrbach A, Larsen CP, Medina Pestana J, Belatacept vs cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study. Am Transplant Congress 2010;83: abstract 143
   Google Scholar
• Grinyo J, Charpentier B, Medina Pestana J, Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies. Am Transplant Congress 2010;83: abstract 144
   Google Scholar
• Rostaing L, Nainan J, del C Rial M, Switch from a CNI- to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a phase II study. Am Transplant Congress 2010;90: abstract 166
   Google Scholar
• Grinyo JM, Mondragon-Ramirez G, Darji P, Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in kidney transplant patients (BENEFIT Study). Am Transplant Congress 2009;70: abstract 236
   Google Scholar
• Ferguson R, Vincenti F, Kaufman B, Immunosuppression with belatacept-based, CNI-avoiding and steroid-avoiding regimens vs a tacrolimus-based, steroid-avoiding regimen in kidney transplant patients: result of a 1-year, randomized study. Am Transplant Congress 2010;150: abstract 372
   Google Scholar
• Hariharan S, McBride MA, Cherikh WS, Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002;62(1):311-18
   PubMed Web of Science ®Google Scholar
• Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcomes. Am J Transplant 2003;3(8):933-41
   PubMed Web of Science ®Google Scholar
• First MR. Renal function as a prediction of long-term graft survival in renal transplant patients. Nephrol Dial Transplant 2003;18(Suppl 1):i3-6
   Google Scholar
• Pascual J, Marcen R, Ortuno J. Renal function: defining long-term success. Nephrol Dial Transplant 2004;19(Suppl 6):vi3-7
   PubMedGoogle Scholar
• Fortun J, Martin-Davila P, Pascual J, Immunosuppressive therapy and infection after kidney transplantation. Transplant Infect Dis 2010. [Epub ahead of print]
   Google Scholar